Characterization of CD133 Antibody-Directed Recellularized Heart Valves

Journal of Cardiovascular Translational Research
J Koudy WilliamsJames E Jordan

Abstract

CD133mAb conjugation (CD133-C) hastens in vivo recellularization of decellularized porcine heart valve scaffolds when placed in the pulmonary position of sheep. We now characterize this early cellularization process 4 h, 3, 7, 14, 30, or 90 days post-implantation. Quantitative immunohistochemistry identified cell types as well as changes in cell markers and developmental cues. CD133(+)/CD31(-) cells adhered to the leaflet surface of CD133-C leaflets by 3 days and transitioned to native leaflet-like CD133(-)/CD31(+) cells by 30 days. Leaflet interstitium became increasingly populated with both alpha-smooth muscle actin (αSMA) and vimentin(+) cells from 14 to 90 days post-implantation. Wnt3a, and beta-catenin proteins were expressed at early (3-14 days) but not later (30-90 days) time points. In contrast, matrix metalloproteinase-2 and periostin proteins were increasingly expressed over 90 days. Thus, early development of CD133-C constructs includes a fairly rapid transition from a precursor cell adhesion/migration/transdifferentiation phenotype to a more mature cell/native valve-like matrix metabolism phenotype.

References

Aug 3, 1999·Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery·V SenthilnathanA Starr
May 1, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Jonathan T ButcherRobert M Nerem
May 27, 2005·Advances in Biochemical Engineering/biotechnology·Elena Rabkin-AikawaFrederick J Schoen
Sep 13, 2005·The International Journal of Biochemistry & Cell Biology·Nigel J BrandMagdi H Yacoub
Sep 26, 2006·The Annals of Thoracic Surgery·Michael S SacksJoseph H Gorman
Oct 21, 2006·Annals of Biomedical Engineering·Karen Mendelson, Frederick J Schoen
Mar 4, 2008·Developmental Biology·Russell A NorrisRoger R Markwald
May 24, 2008·Circulation Research·Kyle Niessen, Aly Karsan
Jan 8, 2009·Tissue Engineering. Part C, Methods·Bryan W TillmanJames J Yoo
Mar 27, 2009·Tissue Engineering. Part a·Dong Joon LeeJames J Yoo
Aug 29, 2009·Circulation Research·Michelle D Combs, Katherine E Yutzey
Dec 8, 2009·Developmental Biology·Christina M AlfieriKatherine E Yutzey
Dec 17, 2010·Circulation·Véronique L RogerUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Feb 15, 2011·Current Opinion in Biotechnology·Frederick J Schoen
Nov 4, 2011·The Journal of Thoracic and Cardiovascular Surgery·James E JordanJames J Yoo
Mar 8, 2012·World Journal of Surgery·Radoslaw A RippelAlexander M Seifalian
Oct 16, 2012·Archives of Cardiovascular Diseases·Roland HenaineJean Ninet
Mar 16, 2013·Tissue Engineering. Part a·Igor TudoracheSerghei Cebotari

❮ Previous
Next ❯

Citations

Dec 3, 2016·Regenerative Medicine·James Koudy Williams, Karl-Erik Andersson
Sep 12, 2017·Journal of Tissue Engineering·Mitchell C VeDepoGabriel L Converse
Nov 13, 2018·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Jinglei WuYi Hong
Jun 14, 2018·Frontiers in Cardiovascular Medicine·Carlijn V C BoutenFrank P T Baaijens
Mar 22, 2020·Pediatric Cardiology·Matthew R RussellDaniel S Levi
Feb 11, 2021·Cardiovascular Engineering and Technology·Mitchell C VeDepoJeffrey G Jacot
May 4, 2021·Bioactive Materials·Eleonora Dal SassoMonica Dettin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomaterial Engineering

Advances in biomaterial engineering have permitted the development of sophisticated drug-releasing materials with a biomimetic 3D support that allow a better control of the microenvironment of transplanted cells. Here is the latest research.